Home

boccale Prevalere Dispendiosamente gabriella farina fatebenefratelli Datato Manovra marcatura

Sabato 7 Aprile corso Unitalsi: "la fine della vita" - CiaoComo
Sabato 7 Aprile corso Unitalsi: "la fine della vita" - CiaoComo

PPT - Gabriella Farina PowerPoint Presentation, free download - ID:1728180
PPT - Gabriella Farina PowerPoint Presentation, free download - ID:1728180

Gabriella e la squadra con 70 donne «La nostra sfida ai tumori» -  Corriere.it
Gabriella e la squadra con 70 donne «La nostra sfida ai tumori» - Corriere.it

Guidelines Adaptation to the COVID-19 Outbreak for the Management of  Hepatocellular Carcinoma | Journal of Laparoendoscopic & Advanced Surgical  Techniques
Guidelines Adaptation to the COVID-19 Outbreak for the Management of Hepatocellular Carcinoma | Journal of Laparoendoscopic & Advanced Surgical Techniques

ASST Fatebenefratelli & SACCO | ESMO
ASST Fatebenefratelli & SACCO | ESMO

FORMATO EUROPEO PER IL CURRICULUM VITAE
FORMATO EUROPEO PER IL CURRICULUM VITAE

PDF) The prognostic role of tumor size in early breast cancer in the era of  molecular biology | Sheila Piva - Academia.edu
PDF) The prognostic role of tumor size in early breast cancer in the era of molecular biology | Sheila Piva - Academia.edu

Overall Survival in Metastatic Breast Cancer Patients in the Third  Millennium: Results of the COSMO Study∗ - Clinical Breast Cancer
Overall Survival in Metastatic Breast Cancer Patients in the Third Millennium: Results of the COSMO Study∗ - Clinical Breast Cancer

Gabriella Farina's research works | Azienda Ospedaliera Fatebenefratelli e  Oftalmico Milano (Fatebenefratelli) and other places
Gabriella Farina's research works | Azienda Ospedaliera Fatebenefratelli e Oftalmico Milano (Fatebenefratelli) and other places

LKB1 mutations are not associated with the efficacy of first-line and  second-line chemotherapy in patients with advanced non-small-cell lung  cancer (NSCLC): a post hoc analysis of the TAILOR trial - ESMO Open
LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial - ESMO Open

ASST Fatebenefratelli & SACCO | ESMO
ASST Fatebenefratelli & SACCO | ESMO

Randomised Phase II Trial (NCT00637975) Evaluating Activity and Toxicity of  Two Different Escalating Strategies for Pregabalin and Oxycodone  Combination Therapy for Neuropathic Pain in Cancer Patients | PLOS ONE
Randomised Phase II Trial (NCT00637975) Evaluating Activity and Toxicity of Two Different Escalating Strategies for Pregabalin and Oxycodone Combination Therapy for Neuropathic Pain in Cancer Patients | PLOS ONE

Diapositiva 1
Diapositiva 1

Presentazione standard di PowerPoint
Presentazione standard di PowerPoint

Nutrients | Free Full-Text | The Role of Nutritional Support for Cancer  Patients in Palliative Care | HTML
Nutrients | Free Full-Text | The Role of Nutritional Support for Cancer Patients in Palliative Care | HTML

Prospective observational study on the impact of the 21-gene assay on  treatment decisions and resources optimization in breast cancer patients in  Lombardy: The BONDX study - The Breast
Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDX study - The Breast

Nutrients | Free Full-Text | The Clinical Value of Nutritional Care before  and during Active Cancer Treatment | HTML
Nutrients | Free Full-Text | The Clinical Value of Nutritional Care before and during Active Cancer Treatment | HTML

20+ "Gabriella Farina" profiles | LinkedIn
20+ "Gabriella Farina" profiles | LinkedIn

20+ "Gabriella Farina" profiles | LinkedIn
20+ "Gabriella Farina" profiles | LinkedIn

Nutritional Support in Cancer patients: update of the Italian Intersociety  Working Group practical recommendations
Nutritional Support in Cancer patients: update of the Italian Intersociety Working Group practical recommendations

Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised  study by the Italian Trials in Medical Oncology (ITMO) Group - Annals of  Oncology
Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group - Annals of Oncology

A randomized, phase 2 study of cetuximab plus cisplatin with or without  paclitaxel for the first-line treatment of patients with recurrent and/or  metastatic squamous cell carcinoma of the head and neck -
A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck -

Palliative Sedation in Terminal Cancer Patients Admitted to Hospice or Home  Care Programs: Does the Setting Matter? Results From a National Multicenter  Observational Study - Journal of Pain and Symptom Management
Palliative Sedation in Terminal Cancer Patients Admitted to Hospice or Home Care Programs: Does the Setting Matter? Results From a National Multicenter Observational Study - Journal of Pain and Symptom Management

Il caregiver in oncologia: una guida per sostenere il malato | Fondazione  Aiom
Il caregiver in oncologia: una guida per sostenere il malato | Fondazione Aiom

Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell  Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients -  Journal of Thoracic Oncology
Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients - Journal of Thoracic Oncology

Palliative Sedation in Terminal Cancer Patients Admitted to Hospice or Home  Care Programs: Does the Setting Matter? Results From a National Multicenter  Observational Study - Journal of Pain and Symptom Management
Palliative Sedation in Terminal Cancer Patients Admitted to Hospice or Home Care Programs: Does the Setting Matter? Results From a National Multicenter Observational Study - Journal of Pain and Symptom Management

Rationale for Treatment and Study Design of TAILOR: A Randomized Phase III  Trial of Second-line Erlotinib Versus Docetaxel in the Treatment of  Patients Affected by Advanced Non–Small-Cell Lung Cancer With the Absence
Rationale for Treatment and Study Design of TAILOR: A Randomized Phase III Trial of Second-line Erlotinib Versus Docetaxel in the Treatment of Patients Affected by Advanced Non–Small-Cell Lung Cancer With the Absence